Shares of Kimball Electronics (KE) tumbled 6.92% in after-hours trading on Thursday, despite the company reporting better-than-expected fourth-quarter results for fiscal 2025. The sharp decline appears to be driven by disappointing guidance for fiscal 2026, which overshadowed the positive quarterly performance.
For Q4 2025, Kimball Electronics reported earnings of $0.34 per share, significantly beating the analyst consensus estimate of $0.15 per share. The company's quarterly sales came in at $380.47 million, also surpassing the expected $333.19 million. Despite these strong results, investors seemed more focused on the outlook for the coming year.
The company's guidance for fiscal 2026 projects net sales in the range of $1.35 billion to $1.45 billion, representing a 2% to 9% decrease compared to fiscal 2025. This anticipated decline is primarily attributed to the loss of a major electronic braking program in Reynosa, Mexico, which is expected to have a $60 million unfavorable impact on annual sales.
Kimball Electronics is pivoting its strategy towards medical contract manufacturing (CMO), seen as a higher-margin opportunity. The company is investing heavily in a new 300,000-square-foot medical facility in Indianapolis, which is set to open in November. While this move is expected to drive long-term growth and profitability, it may pressure near-term results as the company transitions.
Despite the negative stock reaction, Kimball Electronics reported some positive developments. The company has significantly strengthened its balance sheet, reducing debt by 50% year-over-year to $147.5 million. It also generated record operating cash flow of $183.9 million for fiscal 2025 and improved its cash conversion cycle.
However, challenges persist in the automotive and industrial segments, which are offsetting growth in the medical sector. The automotive vertical saw a 13% year-over-year decline in net sales, while the industrial segment dropped 12% when excluding divestitures.
The after-hours plunge suggests that investors are concerned about the near-term revenue decline and the execution risks associated with the company's strategic shift towards medical CMO. While management anticipates a return to positive top-line growth in fiscal 2027, the market appears to be taking a cautious stance on Kimball Electronics' transition period.